1682-39-9

Usage

Uses

Used in Pharmaceutical Research:
5-Fluorobenzoxazol-2-amine is utilized as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and biologically active compounds. Its presence in molecular structures can influence the pharmacokinetics and pharmacodynamics of the resulting compounds, thereby enhancing their therapeutic potential.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-Fluorobenzoxazol-2-amine is employed as a valuable tool for studying structure-activity relationships. Its incorporation into various molecular frameworks aids researchers in understanding how specific structural modifications can affect the biological activity of drug candidates, which is essential for optimizing their efficacy and safety.
Used in Drug Development:
5-Fluorobenzoxazol-2-amine is used as a component in drug development for its potential to be incorporated into molecules with therapeutic applications. 5-Fluorobenzoxazol-2-amine's properties, including the presence of the fluorine atom, can impart specific characteristics to the molecules, such as improved metabolic stability or enhanced binding affinity to target proteins, which are crucial for the treatment of various diseases.
Used in the Treatment of Various Diseases:
Although the specific diseases are not detailed in the provided materials, 5-Fluorobenzoxazol-2-amine holds potential for use in the treatment of a range of diseases. Its application in this context is based on its ability to be part of drug molecules that can target and modulate biological pathways implicated in disease processes, offering new therapeutic options for patients.

InChI:InChI=1/C7H5FN2O/c8-4-1-2-6-5(3-4)10-7(9)11-6/h1-3H,(H2,9,10)

Upstream product

• 506-68-3 bromocyane 
• 399-97-3 2-amino-4-fluorophenol 
• 371-41-5 4-Fluorophenol 
• 271793-71-6 4-fluoro(2-pyrimidinyloxy)benzene 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB

N-(5-Chlorobenzo[d]oxazol-2-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamideox-amide has been identified as a potent inhibitor of Mtb H37Rv, with a minimum inhibitory concentration (MIC) of 0.42 μM. In this study, a series of substituted 2-acylamide-1,3-zole analogues were designed and synthesized, and their anti-Mtb activities were analyzed. In total, 17 compounds were found to be potent anti-Mtb agents, especially against the MDR- and XDR-MTB strains, with MIC values 10 μM. These analogues can inhibit both drug-sensitive and drug-resistant Mtb. Four representative compounds were selected for further profiling, and the results indicate that compound 18 is acceptably safe and has favorable pharmacokinetic (PK) properties. In addition, this compound displays potent activity against Gram-positive bacteria, with MIC values in the range of 1.48–11.86 μM. The data obtained herein suggest that promising anti-Mtb candidates may be developed via structural modification, and that further research is needed to explore other compounds.

ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR

The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant pathogens. Disclosed herein are the compounds of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and their use in the treatment of antimicrobial infection. (Formula (1))

Substituted benzo - 1, 3 - [...] compound, its preparation and use

The invention relates to a substituted benzo-1, 3-miscellaneous azole compound shown in the general formula I, and further relates to a preparation method of the compound and application to the preparation of antituberculosis drugs. The compound provided by the invention has effect not only on mycobacterium tuberculosis sensitive strains, but also on resistant strains which have drug resistance to isoniazid, rifampicin, and other traditional frontline antituberculosis drugs, and is a novel antimycobacterium tuberculosis compound.

Electrochemical intramolecular c-h amination: Synthesis of benzoxazoles and benzothiazoles

A new method for metal-free intramolecular C-H amination has been developed. Electrochemical oxidation of 2-pyrimidyloxybenzenes and 2-pyrimidylthiobenzenes, which can be easily prepared from phenols and thiophenols, respectively, followed by the treatment of the resulting pyrimidinium ions with piperidine gives 2-aminobenzoxazoles and 2-aminobenzothiazoles, respectively.